Trial ID or NCT#

NCT02358889

Status

NOT RECRUITING

Purpose

The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared to ranibizumab 0.5 mg monotherapy in treating patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Official Title

A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Eligibility Criteria

Ages Eligible for Study: Older than 50 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Theodore Leng, MD, FACS
Retina specialist, Ophthalmologic surgeon, Cataract specialist, Ophthalmologist
Assistant Professor of Ophthalmology and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM